London (PRWEB) November 19, 2013
EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of multifactorial origin that can affect any organ or organ systems, resulting in a broad spectrum of clinical manifestations ranging from dermatological involvement to multi-organ failure with episodes of relapses and remissions. The disease has unpredictable natural course and high rates of morbidity and death The incidence and prevalence of SLE varies globally and the variation is attributed to a combination of elements such as the characteristics of the population studied, sex, ethnicity, geographical locations, occupational factors, familial traits, time period involved, and the diagnostic criteria used. Lupus nephritis (LN) or lupus glomerulonephritis is a serious complication of SLE in which the kidneys are affected.
GlobalData epidemiologists utilized data from country-specific studies published in peer-reviewed journals and governmental documents to provide the age- and sex-specific prevalent cases of diagnosed SLE in the respective markets. The forecast methodology and disease diagnosis criteria were consistent across all of the 7MM to allow for a meaningful comparison among them. The SLE prevalent case forecast followed the 1982 American College of Rheumatology classification and the LN cases were segmented according to the WHO 1982 classification.
The report forecast that 2012 had 452,053 diagnosed prevalent cases of SLE in the 7MM, with approximately 60% of the diagnosed prevalent cases (265,562) in the US alone. GlobalData epidemiologists forecast that there will be 488,769 diagnosed prevalent cases of SLE in the 7MM by 2022, with an overall average annual growth rate (AGR) of 0.81% during the forecast period. GlobalData’s epidemiological forecast projected an increase in the diagnosed prevalent cases.
-The Systemic Lupus Erythematosus (SLE) EpiCast Report provides an overview of the risk factors and global trends for SLE for the seven major markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan). GlobalData epidemiologists provide the 10-year epidemiological forecast of the diagnosed prevalent cases of SLE segmented by sex and age and the diagnosed prevalent cases of lupus nephritis (LN) for the 7MM. The prevalent cases of LN in the US, France, Germany, Italy, Spain, and UK are further segmented by severity class (Class I–VI). The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The Systemic Lupus Erythematosus EpiCast report will allow you to -
-Develop business strategies by understanding the trends shaping and driving the global SLE market.
-Quantify patient populations in the global SLE to improve product design, pricing, and launch plans.
-Organize sales and marketing efforts by identifying the age groups, sex, and LN class that present the best opportunities for SLE therapeutics in each of the markets covered.
-Identify the percentage of LN prevalent cases in each severity class.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 10
3.2.1 Women are at a higher risk of developing SLE than men 11
3.2.2 Caucasians are at lower risk of developing SLE than other ethnicities 12
3.2.3 Familial history has been associated with an increased risk of developing SLE 13
3.2.4 Certain occupational and environmental exposures trigger SLE 14
3.3 Global Trends 15
3.3.1 US 16
3.3.2 5EU 17
3.3.3 Japan 20
3.4 Forecast Methodology 20
3.4.1 Sources Used 23
3.4.2 Sources Not Used 27
3.4.3 Forecast Assumptions and Methods 28
3.5 Epidemiological Forecast of SLE (2012–2022) 34
3.5.1 Diagnosed Prevalent Cases of SLE 34
3.5.2 Age-Specific Prevalent Cases of SLE 36
3.5.3 Sex-Specific Prevalent Cases of Diagnosed SLE 38
3.5.4 Age-Standardized Prevalence of SLE 40
3.5.5 Diagnosed Prevalent Cases of LN 41
3.5.6 Prevalent Cases of LN, Segmented by Class 43
3.6 Discussion 45
3.6.1 Conclusions on Epidemiology Trends 45
3.6.2 Limitations of the Analysis 46
3.6.3 Strengths of the Analysis 47
4 Appendix 49
4.1 Bibliography 49
4.2 About the Authors 54
4.2.1 Epidemiologist 54
4.2.2 Reviewers 54
4.2.3 Global Director of Epidemiology and Health Policy 56
4.2.4 Global Head of Healthcare 56
4.3 About GlobalData 57
4.4 About EpiCast 57
4.5 Disclaimer 58
1.1 List of Tables
Table 1: The 1982 Revised ARC Criteria For Classification of Systemic Lupus Erythematosus 9
Table 2: Risk Factors Associated with SLE 10
Table 3: World Health Organization Morphologic Classification of Lupus Nephritis (Modified in 1982) 21
Table 4: Sources of Prevalence Data Used in this Analysis 22
Table 5: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, N, Select Years 2012–2022 35
Table 6: 7MM, Prevalent Cases of Diagnosed SLE, by Age, Both Sexes, N, Row (%), 2012 37
Table 7: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, by Sex, N, Row (%), 2012 38
Table 8: 7MM, Prevalent Cases of Diagnosed LN, All Ages, Both Sexes, N, Select Years 2012–2022 42
Table 9: 6MM, Prevalent Cases in the Different Classes of LN, All Age, Both Sexes, N, Row (%), 2012 43
1.2 List of Figures
Figure 1: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, N, 2012–2022 35
Figure 2: 7MM, Prevalent Cases of Diagnosed SLE, by Age, Both Sexes, N, Row (%), 2012 37
Figure 3: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, 2012 39
Figure 4: 7MM, Age-Standardized Prevalence (%) of Diagnosed SLE, All Ages, by Sex, 2012 40
Figure 5: 7MM, Prevalent Cases of Diagnosed LN, All Ages, Both Sexes, N, 2012–2022 42
Figure 6: 6MM, Prevalent Cases of LN, by Class, All Ages, Both Sexes, 2012 44
Read the full report:
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48
Read the full story at http://www.prweb.com/releases/2013/11/prweb11349155.htm.
Copyright©2012 Vocus, Inc.
All rights reserved